{'52WeekChange': 0.26373625,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Building B',
 'address2': 'EPFL Innovation Park',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.94,
 'askSize': 800,
 'averageDailyVolume10Day': 6245925,
 'averageVolume': 865074,
 'averageVolume10days': 6245925,
 'beta': 0.503383,
 'beta3Year': None,
 'bid': 6.91,
 'bidSize': 1000,
 'bookValue': 2.986,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lausanne',
 'companyOfficers': [],
 'country': 'Switzerland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.07,
 'dayLow': 6.55,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 495830080,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '41 21 345 91 20',
 'fiftyDayAverage': 7.044857,
 'fiftyTwoWeekHigh': 13,
 'fiftyTwoWeekLow': 4.07,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26861774,
 'forwardEps': -0.78,
 'forwardPE': -8.846154,
 'fromCurrency': None,
 'fullTimeEmployees': 115,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.47897997,
 'heldPercentInstitutions': 0.26783,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/acimmune.com',
 'longBusinessSummary': 'AC Immune SA, a clinical stage biopharmaceutical '
                        'company, discovers, designs, and develops therapeutic '
                        'and diagnostic products for the prevention, '
                        'diagnosis, and treatment of neurodegenerative '
                        'diseases associated with protein misfolding. Its '
                        'SupraAntigen and Morphomer platforms are designed to '
                        'generate vaccines, antibodies, and small molecules, '
                        'which selectively interact with misfolded proteins '
                        'that are common in a range of neurodegenerative '
                        "diseases. The company's lead product candidate is "
                        'crenezumab, a humanized, monoclonal, and '
                        'conformation-specific anti-Abeta antibody, which is '
                        'in Phase II clinical prevention trial for the '
                        "treatment of Alzheimer's disease (AD). It is also "
                        'developing ACI-24, an anti-Abeta vaccine candidate '
                        'that is in Phase II clinical study for AD, as well as '
                        'is in Phase Ib clinical study for Down syndrome; '
                        'ACI-35, an anti-Tau vaccine candidate that has '
                        'completed Phase Ib clinical study; RG6100, an '
                        'anti-Tau antibody candidate, which is in Phase II '
                        'clinical study for AD patients; and Tau-PET imaging '
                        'tracer that has completed Phase I clinical study. In '
                        'addition, the company is researching and developing '
                        'Tau Morphomer aggregation inhibitor small molecules '
                        'for AD. Further, it has discovery and pre-clinical '
                        'stage molecules targeting neurodegenerative diseases, '
                        'as well as diagnostics targeting Tau, '
                        'alpha-synuclein, and TDP-43 aggregates. The company '
                        'has license agreements and collaborations with '
                        'Genentech, Inc.; Biogen International GmbH; Janssen '
                        'Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli '
                        'Lilly and Company; Essex Bio-Technology Limited; and '
                        'WuXi Biologics. It also has a research collaboration '
                        'with University of Pennsylvania to focus on '
                        'pathogenic protein TDP-43 in neurodegenerative '
                        'diseases. AC Immune SA was founded in 2003 and is '
                        'headquartered in Lausanne, Switzerland.',
 'longName': 'AC Immune SA',
 'market': 'us_market',
 'marketCap': 495829856,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_22309440',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.67,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '41 21 345 91 21',
 'previousClose': 6.66,
 'priceHint': 2,
 'priceToBook': 2.3107836,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -0.53355,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.07,
 'regularMarketDayLow': 6.55,
 'regularMarketOpen': 6.67,
 'regularMarketPreviousClose': 6.66,
 'regularMarketPrice': 6.67,
 'regularMarketVolume': 420838,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 71859400,
 'sharesPercentSharesOut': 0.0087,
 'sharesShort': 627105,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 666860,
 'shortName': 'AC Immune SA',
 'shortPercentOfFloat': 0.0232,
 'shortRatio': 7.58,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ACIU',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.547,
 'twoHundredDayAverage': 7.4744606,
 'volume': 420838,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.acimmune.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '1015'}